BioLife - BLFS Net earnings per one share for the last twelve months
The annual percentage change in EPS TTM for BioLife Solutions, Inc. (BLFS) demonstrates how its own cryogen production plants in the US impact supply stability. The current 986.30 reflects the metric's baseline level. The company is currently pivoting toward high-margin software, moving away from low-cost equipment. Simultaneously, BioLife Solutions, Inc. (BLFS) is strengthening its status as a key partner in the gene therapy sector by supplying specialized biomaterial preservation systems.
BLFS (BioLife Corp): analytical breakdowns and indicator data
- stock quotes and analyst forecast:
- issuer market value details:
- company book value details:
- debt burden and liquidity indicators:
Debt to Capital BioLife Solutions, Inc.|BLFS - Long-Term Debt to Equity|Short-Term Debt to Equity BioLife|BLFS - Company Total Debt|Debts to Book Capitalization BioLife Solutions Inc|BLFS - Company Long-Term Liabilities|Amount of Current Liabilities BioLife Solutions|Interim Coverage Ratio biolifesolutions.com
- financial results and valuation multiples details:
BLFS - Company Net Income|Expected Net Profit BioLife Solutions, Inc.|BLFS - Price to Earnings Ratio|Price to Future Earnings Ratio BioLife Solutions Inc|BLFS - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio BioLife Solutions Inc|BLFS - Operating profit before deduction of amortization|Earnings per share for the trailing year BioLife Solutions|BLFS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months biolifesolutions.com|BLFS - Earnings per share growth in current year|Projected earnings per share growth rate for next year BioLife Solutions, Inc.
Fundamental valuation:BLFS - biolifesolutions.com
This indicator measures the percentage shift in net earnings per share over the last twelve months relative to the same period last year, allowing investors to filter out market noise and identify the real earnings trend. By analyzing the percentage change in EPS over a rolling year, an investor can see how the integration of BioLife Solutions, Inc. (BLFS) proprietary media into gene therapy protocols converts into actual profit growth.
Direct competitors
Earnings per one share for the last 12 months TEM|QGEN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Ionis Pharmaceuticals, Inc. (IONS)|Net earnings per share for the last 12 months RGEN|RNA: Earnings per share for the trailing year|Earnings per share for the last twelve months CRISPR Therapeutics AG (CRSP)|Net earnings per share for the last four quarters genedx.com|Earnings per share for the last twelve months Ultragenyx RARE|Beam Therapeutics Inc (BEAM) - Net earnings per one share for the last twelve months|SRPT - Earnings per share for the last twelve months|TWST: Earnings per share for the last twelve months|TXG (10x Genomics, Inc.) - Net earnings per share for the last 12 months|intelliatx.com (NTLA) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months STOK|WVE (Wave Life Sciences Ltd) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) MAZE|Net earnings per share for the last four quarters Sionna Corp|Earnings per share for the last twelve months Prime Medicine, Inc. PRME|tayshagtx.com (TSHA) - Net earnings per one share for the last twelve months|QURE - Earnings per share for the last twelve months|MGTX (MeiraGTx Holdings) - Earnings per share for the last 12 months|Regenxbio (RGNX) - Earnings per share for the last twelve months|SLDB - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months OCGN|PACB: Earnings per share for the trailing year|Net earnings per share (EPS TTM) BNTC|Net earnings per share for the last four quarters Design Therapeutics Inc|Earnings per share for the last twelve months Rocket Pharmaceuticals Inc RCKT|FDMT: Earnings per share for the last 12 months|Lexeo - Net earnings per share (EPS TTM)|Korro Bio, Inc. (KRRO) - Net earnings per share for the last 12 months|EDIT (Editas Medicine) - Net earnings per share for the last 12 months|SLN - Net earnings per share for the last four quarters|PRQR (ProQR) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months CDXS|Earnings per share for the last twelve months Sangamo Therapeutics (SGMO)|Earnings per share for the last twelve months NAUT (nautilus.bio)|Net earnings per share (EPS TTM) MGX (Metagenomi)|DTIL (Precision BioSciences Inc.) - Earnings per one share for the last 12 months|GBIO - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Boundless Bio Inc BOLD|XCUR: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months IMNN|Earnings per share for the last twelve months Phio Pharmaceuticals Corp|Earnings per share for the last 12 months MBIO (Mustang Bio Corp)|Net earnings per share (EPS TTM) RNAZ|Net earnings per share (EPS TTM) bionanogenomics.com (BNGO)|Net earnings per share (EPS TTM) APDN (Applied DNA Sciences)|bluebirdbio.com - Earnings per share for the last twelve months|ImmunoPrecise - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Omega Therapeutics Inc OMGA|Singular Genomics Systems Inc (OMIC) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Regulus (RGLS)|Earnings per share for the last twelve months Syros Pharmaceuticals|Earnings per share for the last twelve months TBIO|Net earnings per share (EPS TTM) TCON|Net earnings per share for the last four quarters Unity Biotechnology Inc.
